Bulletin
Investor Alert

New York Markets Open in:

June 24, 2020, 9:10 a.m. EDT

US Analysts Bullish On These Pharma Robinhood Stocks: $CPRX $CRBP $VKTX

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Catalyst Pharmaceuticals Inc. (CPRX)
  • X
    Corbus Pharmaceuticals Holdings Inc. (CRBP)
  • X
    Viking Therapeutics Inc. (VKTX)

or Cancel Already have a watchlist? Log In

Jun 24, 2020 (The Market Signal via Comtex) -- The Market Signal was created as a platform to help investors find the best free Stock Reports on stocks they own. If you are a shareholder or looking for stocks to buy /zigman2/quotes/202806602/composite CPRX -3.95% , /zigman2/quotes/201549545/composite CRBP +8.29% or /zigman2/quotes/204618964/composite VKTX +3.99% then we strongly urge you to join our community by signing up with the link below and getting a completely free research report on each company today.

https://themarketsignal.com/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Catalyst Pharmaceuticals promotes Jeffrey Del Carmen to serve on Executive Leadership Team

https://themarketsignal.com/Free-Report/CPRX

(Click link above or copy, paste and hit enter in your browser for your report)

Catalyst Pharmaceuticals Inc /zigman2/quotes/202806602/composite CPRX -3.95% has over 100,000 investors owning the stock on Robinhood and is 100% Buy rating. The stock closed yesterday at $4.7 at a market capitalization of $486.05 million. On Tuesday, the commercial-stage biopharmaceutical company announced that it is promoting Jeffrey Del Carmen to the post of Chief Commercial Officer, who took up the responsibility of role with immediate effect.

Jeffrey Del Carmen had joined the company in August 2018 as the Senior Vice President of Catalyst's Sales and Marketing division. In the new position, Jeffrey Del Carmen shall be reporting to the CEO of company. He shall be serving on Executive Leadership Team of company.

Additionally, the company has also announced that Pete Curry, Sr. was promoted to the post of Vice President of Sales. He was earlier serving as National Sales Director of the company.

Corbus Pharmaceuticals reported last subject visit in the phase 2b study of potential treatment of cystic fibrosis

https://themarketsignal.com/Free-Report/CRBP

(Click link above or copy, paste and hit enter in your browser for your report)

Corbus Pharmaceuticals Holdings Inc /zigman2/quotes/201549545/composite CRBP +8.29% more than 76,000 investors own the stock on Robinhood and has a 100% buying rating on Robinhood. This company reported, on Monday, its last subject visit in the phase 2b study of a potential drug, lenabasum that is being developed for treatment of cystic fibrosis.

The company reported that the top line data from this study is expected to be released in the third quarter of this year.

Viking Therapeutics' future depends on its potential drug for two liver diseases

https://themarketsignal.com/Free-Report/VKTX

(Click link above or copy, paste and hit enter in your browser for your report)

Almost 80,000 investors of Viking Therapeutics Inc /zigman2/quotes/204618964/composite VKTX +3.99% own the stock on Robinhood and have a 100% buying rating on Robinhood. Viking Therapeutics popped up by 1.91% to close at $8.0 in its last trading session. The market capitalization of this stock as of Tuesday is $586.58 million.

One of the key developments that investors must learn here is that the future of Viking is largely dependent upon its drug, VK2809, which is one of the three drugs in pipeline. The company is conducting clinical trials for demonstrating its effectiveness in treatment of two kinds of liver diseases where there hasn't been any therapy yet- non-alcoholic steatohepatitis and non-alcoholic fatty liver.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

The post US Analysts Bullish On These Pharma Robinhood Stocks: $CPRX $CRBP $VKTX appeared first on The Market Signals .

COMTEX_367318145/2662/2020-06-24T09:09:52

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/202806602/composite
US : U.S.: Nasdaq
$ 4.13
-0.17 -3.95%
Volume: 2.00M
Aug. 3, 2020 4:00p
P/E Ratio
10.25
Dividend Yield
N/A
Market Cap
$444.74 million
Rev. per Employee
$9,804
loading...
/zigman2/quotes/201549545/composite
US : U.S.: Nasdaq
$ 6.79
+0.52 +8.29%
Volume: 1.68M
Aug. 3, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$454.52 million
Rev. per Employee
$62,627
loading...
/zigman2/quotes/204618964/composite
US : U.S.: Nasdaq
$ 7.30
+0.28 +3.99%
Volume: 1.27M
Aug. 3, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$510.76 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/202806602/composite
US : U.S.: Nasdaq
$ 4.13
-0.17 -3.95%
Volume: 2.00M
Aug. 3, 2020 4:00p
P/E Ratio
10.25
Dividend Yield
N/A
Market Cap
$444.74 million
Rev. per Employee
$9,804
loading...
/zigman2/quotes/201549545/composite
US : U.S.: Nasdaq
$ 6.79
+0.52 +8.29%
Volume: 1.68M
Aug. 3, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$454.52 million
Rev. per Employee
$62,627
loading...
/zigman2/quotes/204618964/composite
US : U.S.: Nasdaq
$ 7.30
+0.28 +3.99%
Volume: 1.27M
Aug. 3, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$510.76 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.